Traditional therapeutic strategies for advanced RCC, including surgical resection and targeted therapies such as vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have improved clinical outcomes to some extent (Supplementary Table 1) (6, 7). This evidence concerns the gene VEGFA and renal cell adenocarcinoma.